Intercept Pharmaceuticals
10 Hudson Yards
37th Floor
New York City
New York
10001
United States
Website: https://www.interceptpharma.com/
185 articles with Intercept Pharmaceuticals
-
Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio's pediatric methylmalonic acidemia study is back up and running and another look at Roche's TIGIT flop.
-
Intercept Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis
5/11/2022
Intercept Pharmaceuticals, Inc. today announced the first patient has been dosed in a Phase 2 study evaluating a fixed-dose combination of obeticholic acid (OCA) and bezafibrate (BZF).
-
Intercept Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
5/6/2022
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter ended March 31, 2022.
-
Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450MM, including $405MM Upfront and an Additional $45MM in Contingent Payments
5/5/2022
Agreement includes rights for Advanz to commercialize orphan drug Ocaliva® for PBC outside the U.S., as well as the transition to Advanz of the international commercial and medical infrastructure of Intercept.
-
Intercept to Announce First Quarter 2022 Financial Results on May 6, 2022
5/2/2022
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2022 financial results prior to market open on Friday, May 6, 2022.
-
Intercept to Announce Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022
2/23/2022
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 2021 financial results prior to market open on Wednesday, March 2, 2022.
-
Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASHStudy remains ongoing; top-line data anticipated in Q1 2022 versus near the end of the year
12/20/2021
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), today announced that top-line data from its Phase 3 REVERSE trial will be delayed from our previous guidance of near the end of the year and is now expected in the first quarter of 2022.
-
Intercept Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH
12/9/2021
Intercept Pharmaceuticals, Inc. today announced that it has formally notified the European Medicines Agency (EMA) of its decision to withdraw its Marketing Authorization Application (MAA) for obeticholic acid (OCA) for the treatment of liver fibrosis.
-
Intercept Announces New Long-Term Data Demonstrating Potential of Obeticholic Acid to Improve Transplant-Free Survival in Patients with PBC
11/15/2021
Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced results from a new analysis examining obeticholic acid’s potential to improve transplant-free survival in patients with PBC.
-
Intercept to Present at Upcoming Investor Conferences - Nov 11, 2021
11/11/2021
Intercept Pharmaceuticals, Inc. announced that Jerry Durso, President and Chief Executive Officer of Intercept; M. Michelle Berrey, M.D., M.P.H., President of Research & Development and Chief Medical Officer of Intercept; Linda Richardson, Chief Commercial Officer of Intercept; and Andrew Saik, Chief Financial Officer of Intercept, will participate virtually in fireside chats at the following upcoming investor conferences:.
-
Intercept Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
11/3/2021
Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced its financial results for the quarter ended September 30, 2021.
-
Intercept Announces Late-Breaking Oral Presentation and Poster Presentations at The Liver Meeting
11/2/2021
Intercept Pharmaceuticals, Inc. today announced that multiple abstracts on obeticholic acid (OCA) will be presented at The Liver Meeting 2021, the annual meeting of the American Association for the Study of Liver Diseases (AASLD).
-
Intercept to Announce Third Quarter 2021 Financial Results on November 3, 2021
10/27/2021
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2021 financial results prior to market open on Wednesday, November 3, 2021.
-
Intercept’s COO Takes the Helm as CEO as Company Seeks to Expand Ocaliva Indication After FDA Rej...
12/10/2020
Intercept Pharmaceuticals is currently undergoing a leadership transition, with the company’s Chief Operating officer Jerome Durso taking the helm of the company as its newest President and Chief Executive Officer. -
In an 8-K filing with the U.S. Securities and Exchange Commission, Intercept Pharmaceuticals said it will eliminate approximately 170 employees as part of an effort to streamline the company’s operations and reduce operating expenses.
-
Wrapping up June and ahead of the July 4 holiday, the U.S. Food and Drug Administration (FDA) has a busy two-week period coming up for drug approvals. Here’s a look.
-
The U.S. Food and Drug Administration has a busy week of possible drug approvals on its calendar. Here’s a look.
-
Intercept to Host NASH Commercial Day for Investors on December 16, 2019 in New York
12/10/2019
Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced that it will host a NASH Commercial Day for investors on Monday, December 16, 2019 from 9:00 a.m. to 12:30 p.m. ET in New York City..
-
Intercept Announces New NASH and PBC Data to be Presented at The Liver Meeting® 2019
10/28/2019
New analyses from Phase 3 REGENERATE study evaluating the effects of OCA on non-invasive liver fibrosis tests and NASH patient-reported outcomes
-
As the International Liver Conference continues to unfold in Vienna, multiple companies are presenting data on potential treatments that can address numerous needs. BioSpace takes a look at some of the data.